secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001104659-24-072058
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Phase 2b trial of AV-101 fails primary endpoint; halts Phase 3 and extension
--------------------------------------------------------------------------------

- AV-101 did not meet primary endpoint of PVR improvement at any dose (10, 35, 70 mg BID); p-values all >0.36.
- Secondary endpoint 6MWD also showed no meaningful improvement; LS mean differences ranging -11.7 to +1.3 meters.
- Company halting enrollment and shutting down Phase 3 IMPAHCT and long-term extension study, per advisory committee.
- Cash position ~$100M as of June 15, 2024; CEO calls results unexpected and disappointing.
- Full Phase 2b data release timing to be determined; no new clinical path announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000110465924072058/0001104659-24-072058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000110465924072058/tm2417394d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-072058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer